A new report reveals that messenger RNA (mRNA) technology, used in COVID-19 vaccines, is important in the fight against the Omicron variant. The study found that the Moderna and BioNTech mRNA vaccines still maintained an 85.3% efficacy rate against Omicron after the addition of a third dose. The report also supports the development of mRNA vaccines for future variants.
Key takeaways from the meeting notes:
– mRNA technology is being used in COVID-19 vaccines from Moderna and BioNTech.
– The Omicron variant has multiple sub-lineages, including BA.5, BF.7, BQ.1.1., XBB.1.5, and CH.1.1.
– The Pfizer-BioNTech vaccine has shown 85.3% effectiveness against the Omicron variant.
– The mRNA technology has the potential to be used for other diseases in the future.
– David Heymann, an expert in infectious diseases, believes that mRNA technology has great potential for future vaccine development.